164 related articles for article (PubMed ID: 23014897)
1. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy.
Chen C; Chan A; Yap K
J Oncol Pharm Pract; 2013 Jun; 19(2):111-20. PubMed ID: 23014897
[TBL] [Abstract][Full Text] [Related]
2. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Li S; Liu J; Guo H; Gawade PL; Kim C; Bensink ME; Chandler D
Support Care Cancer; 2020 Jun; 28(6):2637-2649. PubMed ID: 31624920
[TBL] [Abstract][Full Text] [Related]
3. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
Baig H; Somlo B; Eisen M; Stryker S; Bensink M; Morrow PK
J Oncol Pharm Pract; 2019 Oct; 25(7):1576-1585. PubMed ID: 30200842
[TBL] [Abstract][Full Text] [Related]
4. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.
Fust K; Parthan A; Maschio M; Gu Q; Li X; Lyman GH; Tzivelekis S; Villa G; Weinstein MC
Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):39-52. PubMed ID: 28064553
[TBL] [Abstract][Full Text] [Related]
6. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.
Chao C; Page JH; Yang SJ; Rodriguez R; Huynh J; Chia VM
Ann Oncol; 2014 Sep; 25(9):1821-1829. PubMed ID: 24915871
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
Krzemieniecki K; Sevelda P; Erdkamp F; Smakal M; Schwenkglenks M; Puertas J; Trojan A; Szabo Z; Bendall K; Maenpaa J
Support Care Cancer; 2014 Mar; 22(3):667-77. PubMed ID: 24154740
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas.
Chan A; Lee CP; Chiang J; Ng R
Support Care Cancer; 2013 Aug; 21(8):2137-43. PubMed ID: 23471537
[TBL] [Abstract][Full Text] [Related]
9. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
10. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
11. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Fujiwara T; Kenmotsu H; Naito T; Kawamura T; Mamesaya N; Kotake M; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Taira T; Murakami H; Omae K; Mori K; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1229-1237. PubMed ID: 28455585
[TBL] [Abstract][Full Text] [Related]
12. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
14. Management of chemotherapy-induced febrile neutropenia and use of granulocyte colony-stimulating factor in patients with soft tissue or bone sarcoma.
Mazzaro RT; Vaz MV; Badin RC; Bernardina ED; Manaças LRA
J Oncol Pharm Pract; 2023 Sep; 29(6):1428-1436. PubMed ID: 36226408
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim.
Lee M; Yee J; Kim JY; Kim JY; An SH; Lee KE; Gwak HS
Asia Pac J Clin Oncol; 2019 Aug; 15(4):231-237. PubMed ID: 30997742
[TBL] [Abstract][Full Text] [Related]
16. Predictors of the development of febrile neutropenia in chemotherapy for advanced germ cell tumors.
Kobayashi K; Kishida T
Int J Urol; 2024 Feb; 31(2):134-138. PubMed ID: 37915108
[TBL] [Abstract][Full Text] [Related]
17. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
[TBL] [Abstract][Full Text] [Related]
20. Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy.
Kurtti A; Fritz K; Elofson-Disney K; Benefield R
J Oncol Pharm Pract; 2020 Sep; 26(6):1301-1305. PubMed ID: 31810423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
